Description: ProFACT Proteomics, Inc. is an early-stage Delaware C Corporation founded in November 2004. The Company applies its enabling proprietary Proteomics technology, SeraFILE™ to development of therapeutics and diagnostics, principally for cancer. ProFACT has a core executive team in place, initial scientific advisors, three pending patents, one licensed patent, a key university cancer alliance with the University of Medicine and Dentistry of New Jersey (UMDNJ), and has been funded in part from the New Jersey Commission on Science and Technology (NJCST).

Key Competitive Advantage: The capability to present disease-specific enzymatic conformers to drug screens provides an exceptional new path to accelerate drugs to the market. ProFACT is exclusively positioned to exploit this path by generating activity data of baseline normative conditions and perturbations thereof, whether due to disease, drugs, environment or diet. SeraFILE™ profiling strategies are conducive to correlating proteomic data with other areas of Systems Biology in a high-throughput infrastructure, affording ProFACT a place in a range of drug discovery and development regimes including: lead screening, personalized medicine (optimized dosing regimens and stratified patient populations), models for monitoring therapeutic efficacy and disease progression, and industrial prospecting strategies.

Business Model: The company pursues a hybrid business model combining revenues from services with a risk capital investment plan. This will allow ProFACT to grow its biomarker and drug target intellectual property portfolio. The company evaluates in-licensing and out-licensing potential opportunistically and welcomes inquires in this regard.